The role of antithrombotics in secondary stroke prevention

Seminars in Neurology

Volumn 30, Issue 5, 2010, Pages 492-500

  Lazzaro, Marc A ^a   Malhotra, Konark ^a   Mohammad, Yousef M ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

anticoagulation; Antiplatelets; ischemic stroke; secondary stroke prevention

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CILOSTAZOL; CLOPIDOGREL; DABIGATRAN; DIPYRIDAMOLE; HEPARIN; HEPARINOID; LOTRAFIBAN; OLIGOSACCHARIDE; PRASUGREL; RIVAROXABAN; TICLOPIDINE; TRIFLUSAL; WARFARIN; XIMELAGATRAN;

ANTICOAGULATION; ARTICLE; BLEEDING; BRAIN ISCHEMIA; DIARRHEA; DIZZINESS; DRUG EFFECT; DRUG INDICATION; DRUG MECHANISM; ENZYME INHIBITION; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART PALPITATION; HUMAN; LIVER TOXICITY; PRIORITY JOURNAL; SECONDARY PREVENTION;

ANTICOAGULANTS; CYCLOOXYGENASE INHIBITORS; FIBRINOLYTIC AGENTS; HUMANS; PHOSPHODIESTERASE INHIBITORS; PLATELET AGGREGATION INHIBITORS; SECONDARY PREVENTION; STROKE; THROMBOSIS; TICLOPIDINE;

EID: 78650928025     PISSN: 02718235     EISSN: 10989021     Source Type: Journal    
DOI: 10.1055/s-0030-1268860     Document Type: Article

References (43)

1. Grau A J., Weimar C, Buggle F et al. Risk factors, outcome, and treatment in subtypes of ischemic stroke: the German stroke data bank. Stroke 2001 32 11 2559-2566
2. Burn J, Dennis M, Bamford J, Sandercock P, Wade D, Warlow C. Long-term risk of recurrent stroke after a first-ever stroke. The Oxfordshire Community Stroke Project. Stroke 1994 25 2 333-337
3. Messmore H L. Jr, Jeske W P., Wehrmacher W et al. Antiplatelet agents: current drugs and future trends. Hematol Oncol Clin North Am 2005 19 1 87-117, vi vi
4. Collaborative overview of randomised trials of antiplatelet therapyI: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 1994 308 6921 81-106
5. Coull B M., Williams L S., Goldstein L B. et al, Joint Stroke Guideline Development Committee of the American Academy of Neurology American Stroke Association. Anticoagulants and antiplatelet agents in acute ischemic stroke: report of the Joint Stroke Guideline Development Committee of the American Academy of Neurology and the American Stroke Association (a division of the American Heart Association). Stroke 2002 33 7 1934-1942
6. CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet 1997 349 9066 1641-1649
7. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet 1997 349 9065 1569-1581
8. van Kooten F, Ciabattoni G, Patrono C, Schmitz P I., van Gijn J, Koudstaal P J. Evidence for episodic platelet activation in acute ischemic stroke. Stroke 1994 25 2 278-281
9. Patrono C, Roth G J. Aspirin in ischemic cerebrovascular disease. How strong is the case for a different dosing regimen? Stroke 1996 27 4 756-760
10. Farrell B, Godwin J, Richards S, Warlow C. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 1991 54 12 1044-1054
11. Albers G W., Tijssen J G. Antiplatelet therapy: new foundations for optimal treatment decisions. Neurology 1999 53 7, Suppl 4 S25-S31
12. Sacco R L., Adams R, Albers G et al, American Heart Association American Stroke Association Council on Stroke Council on Cardiovascular Radiology and Intervention American Academy of Neurology. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke 2006 37 2 577-617 (Pubitemid 43732031)
13. Ibanez B, Vilahur G, Badimon J J. Pharmacology of thienopyridines: rationale for dual pathway inhibition. Eur Heart J 2006 8 Suppl G G3-G9
14. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996 348 9038 1329-1339
15. Holmes D R. Jr, Dehmer G J., Kaul S, Leifer D, O'Gara P T., Stein C M. ACCF/AHA clopidogrel clinical alert: approaches to the FDA boxed warning: a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol 2010 56 4 321-341
16. Hass W K., Easton J D., Adams H P. Jr et al, Ticlopidine Aspirin Stroke Study Group. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989 321 8 501-507
17. Gorelick P B., Richardson D, Kelly M et al, African American Antiplatelet Stroke Prevention Study Investigators. Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial. JAMA 2003 289 22 2947-2957
18. Stoke Center. Cilostazol Stroke Prevention Study 2. 2010. Available at: http://www.strokecenter.org/trials/trialDetail.aspx?tid=952 Accessed August 1, 2010
19. Diener H C., Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996 143 1-2 1-13
20. Halkes P H., van Gijn J, Kappelle L J., Koudstaal P J., Algra A, ESPRIT Study Group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006 367 9523 1665-1673
21. Sacco R L., Diener H C., Yusuf S et al, PRoFESS Study Group. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 2008 359 12 1238-1251
22. Matas-Guiu J, Ferro J M., Alvarez-Sabn J et al, TACIP Investigators. Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction: the TACIP Study: a randomized, double-blind, multicenter trial. Stroke 2003 34 4 840-848
23. Heeschen C, Hamm C W. Difficulties with oral platelet glycoprotein IIb/IIIa receptor antagonists. Lancet 2000 355 9201 330-331
24. Topol E J., Easton D, Harrington R A. et al, Blockade of the Glycoprotein IIb/IIIa Receptor to Avoid Vascular Occlusion Trial Investigators. Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. Circulation 2003 108 4 399-406
25. Adams H P. Jr, Effron M B., Torner J et al, AbESTT-II Investigators. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of an international phase III trial: Abciximab in Emergency Treatment of Stroke Trial (AbESTT-II). Stroke 2008 39 1 87-99
26. Chen Z M., Jiang L X., Chen Y P. et al, COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005 366 9497 1607-1621
27. Bhatt D L., Fox K A., Hacke W et al, CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006 354 16 1706-1717
28. Diener H C., Bogousslavsky J, Brass L M. et al, MATCH investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004 364 9431 331-337
29. Kennedy J, Hill M D., Ryckborst K J., Eliasziw M, Demchuk A M., Buchan A M., FASTER Investigators. Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial. Lancet Neurol 2007 6 11 961-969
30. Stroke Center. Triple antiplatelets for reducing dependency after ischaemic stroke. 2010. Available at: http://www.strokecenter.org/trials/ TrialDetail.aspx?tid=959 Accessed August 1, 2010
31. Connolly S J., Pogue J, Hart R G. et al, ACTIVE Investigators. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009 360 20 2066-2078
32. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993 342 8882 1255-1262
33. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. Ann Neurol 1997 42 6 857-865
34. Mohr J P., Thompson J L., Lazar R M. et al, Warfarin-Aspirin Recurrent Stroke Study Group. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001 345 20 1444-1451
35. Chimowitz M I., Lynn M J., Howlett-Smith H et al, Warfarin-Aspirin Symptomatic Intracranial Disease Trial Investigators. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 2005 352 13 1305-1316
36. Halkes P H., van Gijn J, Kappelle L J., Koudstaal P J., Algra A, ESPRIT Study Group. Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial. Lancet Neurol 2007 6 2 115-124
37. Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. JAMA 1998 279 16 1265-1272
38. Berge E, Abdelnoor M, Nakstad P H., Sandset P M. Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial. Lancet 2000 355 9211 1205-1210
39. Diener H C., Ringelstein E B., von Kummer R et al, Therapy of Patients With Acute Stroke (TOPAS) Investigators. Treatment of acute ischemic stroke with the low-molecular-weight heparin certoparin: results of the TOPAS trial. Stroke 2001 32 1 22-29
40. Lee A Y., Levine M N., Baker R I. et al, Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003 349 2 146-153
41. Olsson S B., Executive Steering Committee of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003 362 9397 1691-1698
42. Connolly S J., Ezekowitz M D., Yusuf S et al, RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009 361 12 1139-1151
43. ROCKET AF Study Investigators. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J 2010 159 3 340-347, e1